OBJECTIVE: To assess health care costs associated with Cushing disease and to determine changes in overall and comorbidity-related costs after surgical treatment. METHODS: In this retrospective cohort study, patients with Cushing disease were identified from insurance claims databases by International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes for Cushing syndrome (255.0) and either benign pituitary adenomas (227.3) or hypophysectomy (07.6×) between 2004 and 2008. Each patient with Cushing disease was age- and sex-matched with 4 patients with nonfunctioning pituitary adenomas and 10 population control subjects. Comorbid conditions and annual direct health care costs were assessed within each calendar year. Postoperative changes in health care costs and comorbidity-related costs were compared between patients presumed to be in remission and those with presumed persistent disease. RESULTS: Of 877 identified patients with Cushing disease, 79% were female and the average age was 43.4 years. Hypertension, diabetes mellitus, and hyperlipidemia were more common among patients with Cushing disease than in patients with nonfunctioning pituitary adenomas or in control patients (P<.01). For every calendar year studied, patients with Cushing disease had significantly higher total health care costs (2008: $26 440 [Cushing disease] vs $13 708 [nonfunctioning pituitary adenomas] vs $5954 [population control], P<.01). Annual outpatient costs decreased significantly for patients in remission after surgery, and there was a trend towards improvement in overall disease-related costs with remission. A significant increase in postoperative health care costs was observed in those patients not in remission. CONCLUSIONS: Patients with Cushing disease had more comorbidities than patients with nonfunctioning pituitary adenomas or control patients and incurred significantly higher annual health care costs; these costs decreased after successful surgery and increased after unsuccessful surgery.
OBJECTIVE: To assess health care costs associated with Cushing disease and to determine changes in overall and comorbidity-related costs after surgical treatment. METHODS: In this retrospective cohort study, patients with Cushing disease were identified from insurance claims databases by International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes for Cushing syndrome (255.0) and either benign pituitary adenomas (227.3) or hypophysectomy (07.6×) between 2004 and 2008. Each patient with Cushing disease was age- and sex-matched with 4 patients with nonfunctioning pituitary adenomas and 10 population control subjects. Comorbid conditions and annual direct health care costs were assessed within each calendar year. Postoperative changes in health care costs and comorbidity-related costs were compared between patients presumed to be in remission and those with presumed persistent disease. RESULTS: Of 877 identified patients with Cushing disease, 79% were female and the average age was 43.4 years. Hypertension, diabetes mellitus, and hyperlipidemia were more common among patients with Cushing disease than in patients with nonfunctioning pituitary adenomas or in control patients (P<.01). For every calendar year studied, patients with Cushing disease had significantly higher total health care costs (2008: $26 440 [Cushing disease] vs $13 708 [nonfunctioning pituitary adenomas] vs $5954 [population control], P<.01). Annual outpatient costs decreased significantly for patients in remission after surgery, and there was a trend towards improvement in overall disease-related costs with remission. A significant increase in postoperative health care costs was observed in those patients not in remission. CONCLUSIONS:Patients with Cushing disease had more comorbidities than patients with nonfunctioning pituitary adenomas or control patients and incurred significantly higher annual health care costs; these costs decreased after successful surgery and increased after unsuccessful surgery.
Authors: Eliza B Geer; Alejandro Ayala; Vivien Bonert; John D Carmichael; Murray B Gordon; Laurence Katznelson; Ekaterina Manuylova; Ismat Shafiq; Vijaya Surampudi; Ronald S Swerdloff; Michael S Broder; Dasha Cherepanov; Marianne Eagan; Jackie Lee; Qayyim Said; Maureen P Neary; Beverly M K Biller Journal: Pituitary Date: 2017-08 Impact factor: 4.107
Authors: Michael S Broder; Maureen P Neary; Eunice Chang; Dasha Cherepanov; Gordon H Sun; William H Ludlam Journal: Pituitary Date: 2015-08 Impact factor: 4.107
Authors: Daniel J Lobatto; Wilbert B van den Hout; Amir H Zamanipoor Najafabadi; Anath N V Steffens; Cornelie D Andela; Alberto M Pereira; Wilco C Peul; Wouter R van Furth; Nienke R Biermasz; Thea P M Vliet Vlieland Journal: Endocrine Date: 2019-03-22 Impact factor: 3.633
Authors: Merel van der Meulen; Amir H Zamanipoor Najafabadi; Daniel J Lobatto; Wilbert B van den Hout; Cornelie D Andela; Ingrid M Zandbergen; Alberto M Pereira; Wouter R van Furth; Thea P M Vliet Vlieland; Nienke R Biermasz Journal: Pituitary Date: 2020-10-06 Impact factor: 4.107